Related Experiment Video
Updated: Jun 14, 2025
08:05
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
7.8K
CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis
A Samer Al-Homsi1, Todd E DeFor2, Kelli Cole3
1Donald and Barbara Zucker School of Medicine at Northwell I Hofstra University, Hempstead, New York; Northwell Cancer Institute, New Hyde Park, New York.
Transplantation and Cellular Therapy
|August 29, 2024
Summary
The CAST regimen (post-transplant cyclophosphamide, abatacept, short-term tacrolimus) shows promise in preventing graft-versus-host disease (GvHD) after haploidentical stem cell transplants. This approach significantly reduced relapse rates and improved disease-free survival.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Graft-versus-host disease (GvHD) remains a significant complication following allogeneic stem cell transplantation.
- Post-transplant cyclophosphamide (PTCy) combined with other immunosuppressants has emerged as a strategy to mitigate GvHD.
- The CAST regimen, incorporating PTCy, abatacept, and a short course of tacrolimus, was previously reported to yield excellent GvHD prevention outcomes.
Purpose of the Study:
- To validate the efficacy of the CAST regimen in preventing GvHD and improving survival outcomes.
- To compare the CAST regimen against a standard PTCy-based immunosuppression protocol using propensity score matching.
- To assess the impact of the CAST regimen on GvHD incidence, relapse rates, and overall survival.
Main Methods:
- A propensity score-matched analysis was conducted, comparing patients receiving the CAST regimen with a control cohort receiving PTCy, tacrolimus, and mycophenolate mofetil.
- Nearest neighbor matching was employed to ensure balance in patient covariates between the two groups.
- Key outcomes assessed included acute GvHD grades II-IV, GvHD- and relapse-free survival (GRFS), relapse incidence, and disease-free survival (DFS).
Main Results:
- The CAST cohort showed a trend towards lower rates of acute GvHD (16.7% vs. 28.6%) and improved 1-year GRFS (66.7% vs. 47.6%), though these did not reach statistical significance.
- A statistically significant reduction in relapse incidence was observed in the CAST group (9.5% vs. 26.2%, P = .045).
- The CAST regimen was associated with significantly improved disease-free survival (85.7% vs. 61.9%, P = .01).
Conclusions:
- The CAST regimen demonstrates a significant benefit in reducing relapse rates and enhancing disease-free survival following haploidentical stem cell transplantation.
- While trends suggest improved GvHD prevention, further investigation with larger cohorts or randomized trials is warranted.
- The findings support the investigation of the CAST regimen in a prospective randomized clinical trial to confirm its efficacy in GvHD prevention and overall survival.
